Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96FC9

UPID:
DDX11_HUMAN

ALTERNATIVE NAMES:
CHL1-related protein 1; DEAD/H-box protein 11; Keratinocyte growth factor-regulated gene 2 protein

ALTERNATIVE UPACC:
Q96FC9; Q13333; Q86VQ4; Q86W62; Q92498; Q92770; Q92998; Q92999

BACKGROUND:
The ATP-dependent DNA helicase DDX11 is crucial for maintaining genomic stability, participating in processes such as DNA replication and repair. It exhibits helicase and ATPase activities, essential for resolving DNA replication issues and ensuring chromosome segregation accuracy. DDX11's interaction with non-coding RNAs highlights its regulatory complexity in genomic functions.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Warsaw breakage syndrome, a condition marked by severe developmental anomalies and genomic instability, ATP-dependent DNA helicase DDX11 presents a significant target for therapeutic intervention. Exploring DDX11's mechanisms further could lead to novel treatments for diseases caused by genomic instability.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.